New research shows that early peanut introduction at 4 to 11 months reduces peanut allergies by 43% in children under 3, ...

AbbVieABBV leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira and its aesthetics ...

AbbVie Inc (ABBV) surpasses earnings expectations with robust growth in immunology and neuroscience, despite facing significant Humira sales decline.

Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million ...

AbbVie revealed it has raised its annual profit forecast for 2025 after sales of its newest immunology drugs Skyrizi and Rinvoq strengthened the company’s Q3 sales number, exceeding expectations set ...

AbbVie raised its earnings guidance for 2025 and added to its quarterly dividend after another strong quarter of revenue ...

AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, ...

AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ...

AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped ...

(Reuters) -AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), today announced that it will ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...